These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23328431)

  • 1. [Effects of modification of transferrin on cytotoxicity and intracellular delivery of paclitaxel loaded PLGA nanoparticles].
    Jin SH; Li NC; Zhang ZH; Na YQ
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(44):3151-4. PubMed ID: 23328431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.
    Cui YN; Xu QX; Davoodi P; Wang DP; Wang CH
    Acta Pharmacol Sin; 2017 Jun; 38(6):943-953. PubMed ID: 28552909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model.
    Shah N; Chaudhari K; Dantuluri P; Murthy RS; Das S
    J Drug Target; 2009 Aug; 17(7):533-42. PubMed ID: 19530913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
    Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
    Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles.
    Kuo YC; Lin PI; Wang CC
    Nanomedicine (Lond); 2011 Aug; 6(6):1011-26. PubMed ID: 21707298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E-Oligo(methyl diglycol l-glutamate) as a Biocompatible and Functional Surfactant for Facile Preparation of Active Tumor-Targeting PLGA Nanoparticles.
    Wu J; Zhang J; Deng C; Meng F; Zhong Z
    Biomacromolecules; 2016 Jul; 17(7):2367-74. PubMed ID: 27305935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells.
    Nag M; Gajbhiye V; Kesharwani P; Jain NK
    Colloids Surf B Biointerfaces; 2016 Dec; 148():363-370. PubMed ID: 27632697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
    Liu Y; Pan J; Feng SS
    Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
    Gullotti E; Park J; Yeo Y
    Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.
    Cui Y; Xu Q; Chow PK; Wang D; Wang CH
    Biomaterials; 2013 Nov; 34(33):8511-20. PubMed ID: 23932498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles.
    He X; Ma J; Mercado AE; Xu W; Jabbari E
    Pharm Res; 2008 Jul; 25(7):1552-62. PubMed ID: 18196205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells.
    Mitra M; Misra R; Harilal A; Sahoo SK; Krishnakumar S
    Mol Vis; 2011; 17():2724-37. PubMed ID: 22065926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
    Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
    Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of surfactants on the properties of PLGA nanoparticles.
    Menon JU; Kona S; Wadajkar AS; Desai F; Vadla A; Nguyen KT
    J Biomed Mater Res A; 2012 Aug; 100(8):1998-2005. PubMed ID: 22566409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein functionalized tramadol-loaded PLGA nanoparticles: preparation, optimization, stability and pharmacodynamic studies.
    Lalani J; Rathi M; Lalan M; Misra A
    Drug Dev Ind Pharm; 2013 Jun; 39(6):854-64. PubMed ID: 22799442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.
    Xu Q; Liu Y; Su S; Li W; Chen C; Wu Y
    Biomaterials; 2012 Feb; 33(5):1627-39. PubMed ID: 22118775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation.
    Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M
    Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor.
    Yang R; Shim WS; Cui FD; Cheng G; Han X; Jin QR; Kim DD; Chung SJ; Shim CK
    Int J Pharm; 2009 Apr; 371(1-2):142-7. PubMed ID: 19118614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention.
    Sahoo SK; Labhasetwar V
    Mol Pharm; 2005; 2(5):373-83. PubMed ID: 16196490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.